182
Participants
Start Date
November 6, 2023
Primary Completion Date
July 14, 2025
Study Completion Date
August 4, 2025
PIPE-307 Dose A
Subjects will receive daily oral doses of PIPE-307
PIPE-307 Dose B
Subjects will receive daily oral doses of PIPE-307
Placebo
Subjects will receive daily oral matching dose of Placebo
Neurological Associates of Long Island, P.C., Lake Success
Dent Neurologic Institute, Amherst
Shepherd Center, Atlanta
MS and Neuromuscular Center of Excellence, Clearwater
Aqualane Clinical Research, Naples
Sibyl Wray Neurology PC, Knoxville
Washington University School of Medicine, St Louis
University of Kansas Medical Center, Kansas City
Oklahoma Research Foundation - MS Center of Excellence, Oklahoma City
University of Texas Health Science Center at Houston, Houston
Clinical Trial Network, Houston
Bhupesh Dihenia, MD, PA, Lubbock
Colorado Springs Neurological Associates, Colorado Springs
Xenosciences, Phoenix
Arizona Neuroscience Research, LLC, Phoenix
University of New Mexico/Health Science Center/MIND Imaging Center/MS Specialty Clinic, Albuquerque
Alta Bates Summit Medical Center, Berkeley
Virginia Mason Medical Center, Seattle
UW Medicine MS Center, Seattle
Multicare Neuroscience Center of Washington, Tacoma
Neurology Center of New England P.C., Foxborough
Lead Sponsor
Contineum Therapeutics
INDUSTRY